Adeptus Biotechnologies Stock Rating Maintained by BTIG

AI Summary

BTIG has reiterated its stock rating on Adeptus Biotechnologies, following the company's strategic decision to split its business. This move is intended to focus on core areas and potentially unlock shareholder value. No specific numbers related to financial metrics or projected impacts are available in the report. The decision is positioned to strengthen Adeptus's market presence and operational efficiency, impacting investor sentiment positively.